Tempus AI Shares Drop 1.99% as Trading Volume Slumps to 164th in Market Rankings

On October 13, 2025, Tempus AI (TEM) closed with a 1.99% decline, trading at a volume of $0.67 billion, marking a 29.3% drop from the previous day’s activity. The stock ranked 164th in trading volume among listed equities, indicating subdued market participation despite its recent volatility.

Recent developments suggest mixed sentiment toward the biotech firm. A regulatory update highlighted ongoing clinical trials for Tempus’ AI-driven diagnostics, which analysts note could accelerate product commercialization timelines. However, investor caution emerged following a muted response to quarterly earnings guidance, with the company projecting slower-than-expected revenue growth in its core genomic analysis segment.

Market participants also cited broader sector headwinds affecting medtech stocks, as rising interest rates pressured long-term valuation models. Tempus’ reliance on capital-intensive R&D programs appears to amplify its sensitivity to macroeconomic shifts, particularly in the healthcare technology space.

Back-test results for a one-day “RSI Oversold” strategy on NVDA (2022-01-01 → 2025-10-13) show a cumulative return of 29.66%, annualized at 8.02%. The strategy’s Sharpe ratio of 0.53 reflects moderate risk-adjusted performance, with a maximum drawdown of 12.9%. Short-term rebounds post-deep RSI pullbacks were captured effectively, though gains were capped by the one-day holding rule. The RSI <30 entry filter helped avoid prolonged downturns, but extending holding periods or adding profit-taking rules could enhance returns.